Fenofibrate High TG in Patients with Type 2 Diabetes after PCI

Objective Through prospective randomized comparative study,to observe the clinical effects of fenofibrate combined with atorvastatin on the high TG type 2 diabetics after DES-PCI.Methods 522 DES-PCI postoperative patients of the high TG type 2 diabetic were selected on the criteria and divided randomly into Fenofibrate combined with atorvastatin group and Atorvastatin group.The 249 patients in the combined group ware treated with Fenofibrate 200mg/d in the morning and Atorvastatin 20mg/d at night.The 273 patients in Atorvastatin group were treated with Atorvastatin 20mg/d at night.The occurrence of major adverse cardiovascular events,lipid-lowering effect and safety in the two groups were comparing during the entire course of treatment totaling 12 months.Results In the hospitalization,the incidence of adverse cardiac and serum TG in the combined group was significantly lower than it in Atorvastatin group(P0.05).But the incidence of HDL-C in the combined group was significantly higher than it in the atorvastatin group(P0.05).The incidence of adverse reactions in two groups is similar.Conclusion Fenofibrate combined with atorvastatin can significantly improve the prognosis of the high TG type 2 diabetics after DES-PCI.Fenofibrate combined with atorvastatin is safe and effective.